A. Dimitrios Colevas, MD

4.9/5

A. Dimitrios Colevas, MD

Medical oncologist, Head and neck specialist, Cutaneous oncology specialist

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

View Professional Summary

Insurance Coverage

Online Second Opinion Program

Resources for Referring Physicians

Professional Summary

Education & Certifications

Residency: Johns Hopkins University School of Medicine (1992) MD
Internship: Johns Hopkins University School of Medicine (1990) MD
Medical Education: Johns Hopkins University School of Medicine (1989) MD
- Board Certification: American Board of Internal Medicine, Medical Oncology (1995)
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (1995) MA
- B. A., Columbia, Chemistry (1985)
- M.D., Johns Hopkins, Medicine (1989)

View More Education & Certifications

Publications

An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies
Tishler, R. B., Busse, P. M., Norris, C. M., Rossi, R., Poulin, M., Thornhill, L., … Posner, M. R. (1999). An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 43(5), 1001–1008.
The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck.
Posner, Johnston, Tishler, ANDERSEN, Fiorentino, Busse, … NORRIS. (1998). The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck. Oncologist, 3(6), 424–431.
Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck 20: 758-762, 1998)
Colevas, A. D. (1999). Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck 20: 758-762, 1998). Head & Neck, 21(6), 582-?
- Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck
  Colevas, A. D., Norris, C. M., Tishler, R. B., Fried, M. P., Gomolin, H. I., Amrein, P., … Posner, M. R. (1999). Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. JOURNAL OF CLINICAL ONCOLOGY, 17(11), 3503–3511.
- A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck
  Colevas, A. D., Adak, S., Amrein, P. C., Barton, J. J., Costello, R., & Posner, M. R. (2000). A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. ANNALS OF ONCOLOGY, 11(5), 535–539.
- The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck
  Posner, M. R., Colevas, A. D., & Tishler, R. B. (2000). The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. SEMINARS IN ONCOLOGY, 27(4), 13–24.
- Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck
  Posner, M. R., Glisson, B., Frenette, G., al-Sarraf, M., Colevas, A. D., Norris, C. M., … Garay, C. A. (2001). Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. JOURNAL OF CLINICAL ONCOLOGY, 19(4), 1096–1104.
- NCCN Practice Guidelines for head and neck cancers
  Forastiere, A. A., Pfister, D. G., Ang, K., Brockstein, B., Colevas, A. D., Ellenhorn, J., … Wolf, G. T. (2000). NCCN Practice Guidelines for head and neck cancers. ONCOLOGY-NEW YORK, 14(11A), 163–194.
- A Phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck
  Colevas, A. D., Amrein, P. C., Gomolin, H., Barton, J. J., Read, R. R., Adak, S., … Posner, M. R. (2001). A Phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. CANCER, 92(2), 326–331.
- Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550)
  Colevas, A. D., West, P. J., & Cheson, B. D. (2001). Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550). ONCOLOGY-NEW YORK, 15(9), 1168-?
- Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck
  Colevas, A. D., Read, R., Thornhill, J., Adak, S., Tishler, R., Busse, P., … Posner, M. (2001). Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 51(3), 599–604.
- Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN)
  Colevas, A. D., Norris, C. M., Tishler, R. B., Lamb, C. C., Fried, M. P., Goguen, L. A., … Posner, M. R. (2002). Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 25(2), 153–159.
- A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck
  Tishler, R. B., Norris, C. M., Colevas, A. D., Lamb, C. C., Karp, D., Busse, P. M., … Posner, M. R. (2002). A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. CANCER, 95(7), 1472–1481.
- Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck - The Dana Farber Cancer Institute experience
  Haddad, R., Colevas, A. D., Tishler, R., Busse, P., Goguen, L., Sullivan, C., … Posner, M. (2003). Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck - The Dana Farber Cancer Institute experience. CANCER, 97(2), 412–418.
- Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial
  Karp, J. E., Ross, D. D., Yang, W. D., Tidwell, M. L., Wei, Y. T., Greer, J., … Colevas, A. D. (2003). Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial. CLINICAL CANCER RESEARCH, 9(1), 307–315.
- Organ preservation-induction chemotherapy.
  Colevas, A. D. (2003). Organ preservation-induction chemotherapy. Cancer Treatment and Research, 114, 213–234.
- Development of investigational radiation modifiers
  Colevas, A. D., Brown, J. M., Hahn, S., Mitchell, J., Camphausen, K., & Coleman, C. N. (2003). Development of investigational radiation modifiers. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 95(9), 646–51.
- CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
  Trotti, A., Colevas, A. D., SETSER, A., Rusch, V., Jaques, D., Budach, V., … Rubin, P. (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. SEMINARS IN RADIATION ONCOLOGY, 13(3), 176–181.
- Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
  Haddad, R., Colevas, A. D., Krane, J. F., Cooper, D., Glisson, B., Amrein, P. C., … Posner, M. (2003). Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. ORAL ONCOLOGY, 39(7), 724–727.
- HER2 expression in salivary gland carcinomas: Dependence on histological subtype
  Glisson, B., Colevas, A. D., Haddad, R., Krane, J., El-Naggar, A., Kies, M., … Posner, M. (2004). HER2 expression in salivary gland carcinomas: Dependence on histological subtype. CLINICAL CANCER RESEARCH, 10(3), 944–946.
- Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
  Burdette-Radoux, S., Tozer, R. G., Lohmann, R. C., Quirt, I., Ernst, D. S., Walsh, W., … Eisenhauer, E. A. (2004). Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. INVESTIGATIONAL NEW DRUGS, 22(3), 315–322.
- The clinical development of new mitotic inhibitors that stabilize the microtubule
  Mani, S., Macapinlac, M., Goel, S., Verdier-Pinard, D., Fojo, T., Rothenberg, M., & Colevas, D. (2004). The clinical development of new mitotic inhibitors that stabilize the microtubule. ANTI-CANCER DRUGS, 15(6), 553–58.
- Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent
  Colevas, A. D., Scharf, O., & Schoenfeldt, M. (2004). Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent. ONCOLOGY-NEW YORK, 18(14), 1778-?
- Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
  Galsky, M. D., Small, E. J., Oh, W. K., Chen, I., Smith, D. C., Colevas, A. D., … Kelly, W. K. (2005). Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(7), 1439–1446.
- Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma
  Amrein, P. C., Clark, J. R., Supko, J. G., Fabian, R. L., Wang, C. C., Colevas, A. D., … McIntyre, J. F. (2005). Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. CANCER, 104(7), 1418–1427.
- Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111
  Hussain, M., Tangen, C. M., Lara, P. N., Vaishampayan, U. N., Petrylak, D. P., Colevas, A. D., … Crawford, E. D. (2005). Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111. JOURNAL OF CLINICAL ONCOLOGY, 23(34), 8724–8729.
- Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
  Karp, J. E., Passaniti, A., Gojo, I., Kaufmann, S., Bible, K., Garimella, T. S., … Bauer, K. S. (2005). Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. CLINICAL CANCER RESEARCH, 11(23), 8403–8412.
- In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
  Rudek, M. A., Zhao, M., Smith, N. F., Robey, R. W., He, P., Hallur, G., … Baker, S. D. (2005). In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. CLINICAL CANCER RESEARCH, 11(23), 8503–8511.
- Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design
  Beekman, K. W., Colevas, A. D., Cooney, K., DiPaola, R., Dunn, R. L., Gross, M., … Hussain, M. (2006). Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design. CLINICAL GENITOURINARY CANCER, 4(4), 299–302.
- Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck
  Colevas, A. D. (2006). Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. JOURNAL OF CLINICAL ONCOLOGY, 24(17), 2644–2652.
- Adverse event reporting in publications compared with sponsor database for cancer clinical trials
  Scharf, O., & Colevas, A. D. (2006). Adverse event reporting in publications compared with sponsor database for cancer clinical trials. JOURNAL OF CLINICAL ONCOLOGY, 24(24), 3933–3938.
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
  Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., … Grever, M. R. (2007). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. BLOOD, 109(2), 399–404.
- Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
  Messersmith, W. A., Rudek, M. A., Baker, S. D., Zhao, M., Collins, C., Colevas, A. D., … Wolff, A. C. (2007). Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. EUROPEAN JOURNAL OF CANCER, 43(1), 78–86.
- A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
  Hensley, M. L., Dizon, D., Derosa, F., Venkatraman, E., Sabbatini, P., Chi, D. S., … Aghajanian, C. (2007). A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 25(4), 335–341.
- A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
  Posadas, E. M., Undevia, S., Manchen, E., Wade, J. L., Colevas, A. D., Karrison, T., … Stadler, W. M. (2007). A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. CANCER BIOLOGY & THERAPY, 6(4), 490–493.
- Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
  Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., … Grossman, S. A. (2007). Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. JOURNAL OF CLINICAL ONCOLOGY, 25(13), 1651–1657.
- Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
  Albert, J. M., Cao, C., Kim, K. W., Willey, C. D., Geng, L., Xiao, D., … Lu, B. (2007). Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. CLINICAL CANCER RESEARCH, 13(10), 3033–3042.
- Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia
  Karp, J. E., Smith, B. D., Levis, M. J., Gore, S. D., Greer, J., Hattenburg, C., … Colevas, A. D. (2007). Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia. CLINICAL CANCER RESEARCH, 13(15), 4467–4473.
- Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
  Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., … Haddad, R. I. (2007). Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. NEW ENGLAND JOURNAL OF MEDICINE, 357(17), 1705–1715.
- Patient-reported outcomes and the evolution of adverse event reporting in oncology
  Trotti, A., Colevas, A. D., Setser, A., & Basch, E. (2007). Patient-reported outcomes and the evolution of adverse event reporting in oncology. JOURNAL OF CLINICAL ONCOLOGY, 25(32), 5121–27.
- Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
  Tang, P. A., Siu, L. L., Chen, E. X., Hotte, S. J., Chia, S., Schwarz, J. K., … Winquist, E. (2008). Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. INVESTIGATIONAL NEW DRUGS. ISTANBUL,TURKEY,TURKEY,TURKEY,TURKEY,TURKEY,TURKEY: SPRINGER.
- A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
  O'Connor, O. A., Portlock, C., Moskowitz, C., Straus, D., Hamlin, P., Stubblefield, M., … Zelenetz, A. (2008). A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 143(2), 201–209.
- Head and neck cancers.
  Forastiere, A. A., Ang, K.-K., Brizel, D., Brockstein, B. E., Burtness, B. A., Cmelak, A. J., … Worden, F. (2008). Head and neck cancers. Journal of the National Comprehensive Cancer Network , 6(7), 646–695.
- LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD-AND-NECK CANCER
  Citrin, D., Mansueti, J., Likhacheva, A., Sciuto, L., Albert, P. S., Rudy, S. F., … Van Waes, C. (2009). LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD-AND-NECK CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 74(4), 1040–46.
- MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CANCER
  Van Waes, C., Allen, C. T., Citrin, D., Gius, D., Colevas, A. D., Harold, N. A., … Morris, J. C. (2010). MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(2), 447–454.
- HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA
  Filion, E. J., McClure, L. A., Huang, D., Seng, K., Kaplan, M. J., Colevas, A. D., … Le, Q.-T. (2010). HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 32(10), 1336–44.
- INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
  Daly, M. E., Le, Q.-T., Jain, A. K., Maxim, P. G., Hsu, A., Loo, B. W., … Chang, D. T. (2011). INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 33(1), 103–11.
- A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
  Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., Kumar, A., … Wakelee, H. A. (2010). A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 5(11), 1821–25.
- Head and Neck Cancers
  Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, D., … Worden, F. (2011). Head and Neck Cancers. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(6), 596–649.
- Controversies in the Locoregional Management of Head and Neck Cancer
  Brizel, D. M., Lydiatt, W., & Colevas, A. D. (2011). Controversies in the Locoregional Management of Head and Neck Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(6), 653–62.
- Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients
  Cao, H., Banh, A., Kwok, S., Shi, X., Wu, S., Krakow, T., … Quynh-Thu Le, Q. T. (2012). Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(3), E351–E358.
- Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure
  Wiegner, E. A., Daly, M. E., Murphy, J. D., Abelson, J., Chapman, C. H., Chung, M., … Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. SAN DIEGO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: ELSEVIER SCIENCE INC.
- A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
  Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., Pedro-Salcedo, M. S., … Wakelee, H. A. (2012). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(4), 1013–20.
- Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
  Lee, N. Y., Zhang, Q., Pfister, D. G., Kim, J., Garden, A. S., Mechalakos, J., … Ang, K. K. (2012). Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. LANCET ONCOLOGY, 13(2), 172–80.
- Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.
  Tang, C., Murphy, J. D., Khong, B., La, T. H., Kong, C., Fischbein, N. J., … Le, Q.-T. (2012). Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics, 83(5), 1514–20.
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
  Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., … Levy, R. (2012). Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. JOURNAL OF CLINICAL INVESTIGATION, 122(3), 1066–75.
- Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors
  Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., Clemens, P. L., … Marshall, J. L. (2012). Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 30(6), 2364–70.
- Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies
  Bose, P., Perkins, E. B., Honeycut, C., Wellons, M. D., Stefan, T., Jacobberger, J. W., … Grant, S. (2012). Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(6), 1657–67.
- Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer
  Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., Ganjoo, K., … Wakelee, H. A. (2012). Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. CANCER INVESTIGATION, 30(3), 231–35.
- Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
  Trakul, N., Chang, C. N., Harris, J., Chapman, C., Rao, A., Shen, J., … Diehn, M. (2012). Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), 231–37.
- Mucosal Melanoma of the Head and Neck
  Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B., Cmelak, A. J., Dimitrios Colevas, A., … Schuller, D. E. (2012). Mucosal Melanoma of the Head and Neck. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(3), 320–338.
- Stereotactic radiosurgery for retreatment of gross perineural invasion in recurrent cutaneous squamous cell carcinoma of the head and neck.
  Tang, C., Fischbein, N. J., Murphy, J. D., Chu, K. P., Bavan, B., Dieterich, S., … Le, Q.-T. (2013). Stereotactic radiosurgery for retreatment of gross perineural invasion in recurrent cutaneous squamous cell carcinoma of the head and neck. American Journal of Clinical Oncology, 36(3), 293–98.
- A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261
  Bible, K. C., Peethambaram, P. P., Oberg, A. L., Maples, W., Groteluschen, D. L., Boente, M., … Erlichman, C. (2012). A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261. GYNECOLOGIC ONCOLOGY, 127(1), 55–62.
- A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
  Kim, K. B., Prieto, V., Joseph, R. W., Diwan, A. H., Gallick, G. E., Papadopoulos, N. E., … Colevas, A. D. (2012). A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. MELANOMA RESEARCH, 22(4), 294–301.
- A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
  Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R. A., Colevas, A. D., Shepherd, F. A., … Wakelee, H. A. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 107(4), 604–11.
- Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential
  LoRusso, P. M., Piha-Paul, S. A., Mita, M., Colevas, A. D., Malhi, V., Colburn, D., … Graham, R. A. (2013). Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 71(1), 193–202.
- The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck.
  Russell, J. S., & Colevas, A. D. (2012). The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemotherapy Research and Practice, 2012, 761518-?
- Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence.
  Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., … Yao, M. (2013). Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer, 119(7), 1349–56.
- Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.
  Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., & Chang, A. L. S. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. British Journal of Dermatology, 169(3), 673–76.
- Long-Term Outcomes of Surgery Followed by Radiation Therapy for Minor Salivary Gland Carcinomas
  Zeidan, Y. H., Shultz, D. B., Murphy, J. D., Chan, C., Kaplan, M. J., Colevas, A. D., … Le, Q.-T. (2013). Long-Term Outcomes of Surgery Followed by Radiation Therapy for Minor Salivary Gland Carcinomas. LARYNGOSCOPE, 123(11), 2675–80.
- Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity
  Colevas, A. D. (2014). Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 36(1), 34–42.
- Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary.
  Percival, M.-E. E., & Colevas, A. D. (2013). Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology.
- Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT.
  Colevas, A. D. (1997). Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT. Oncology (Williston Park, N.Y.), 11(9), 86–89.
- Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial
  Colevas, A. D., Busse, P. M., Norris, C. M., Fried, M., Tishler, R. B., Poulin, M., … Posner, M. R. (1998). Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial. JOURNAL OF CLINICAL ONCOLOGY, 16(4), 1331–1339.
- Docetaxel in head and neck cancer - A review
  Colevas, A. D., & Posner, M. R. (1998). Docetaxel in head and neck cancer - A review. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 21(5), 482–486.
- Intramucosal spread of malignant melanoma of the oral cavity
  Bhattacharyya, N., Norris, C. M., Colevas, A. D., & Chasse, T. A. (1998). Intramucosal spread of malignant melanoma of the oral cavity. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 119(6), 711–711.
- ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).
  Marur, S., Lee, J.-W., Cmelak, A., Zhao, W., Westra, W. H., Chung, C. H., … Burtness, B. (2012). ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab
  Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Scheeren, F., … Levy, R. (2012). Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- Quantification of pre-treatment metabolic tumor growth rate in lung cancer
  Eastham, D., Chapman, C. H., Rao, A. K., Balasubramanian, N., Quon, A., Vasanawala, M. S., … Loo, B. W. (2009). Quantification of pre-treatment metabolic tumor growth rate in lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S733–S733.
- Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?
  Eastham, D. V., Chapman, C. H., Rao, A. K., Narasimhan, B., Quon, A., Vasanawala, M. S., … Loo, B. W. (2009). Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S446–S446.
- Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors
  Chang, C. N., Zhou, L. Y., MacFarlane, G., Tran, P., Rao, A., Chapman, C., … Loo, B. W. (2009). Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Phase Ib, multicenter, single-blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT).
  Limaye, S. A., Sonis, S. T., Cilli, F., Colevas, A. D., Brennan, M., Hu, K., … Murphy, B. A. (2012). Phase Ib, multicenter, single-blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT). JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- Long term followup of a phase I study of concurrent paclitaxel and radiation for locally advanced squamous cell carcinoma of the head and neck
  Mansueti, J., Likhacheva, A., Albert, P., Scuito, L., Harold, N., Rudy, S., … Citrin, D. (2007). Long term followup of a phase I study of concurrent paclitaxel and radiation for locally advanced squamous cell carcinoma of the head and neck. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S444–S444.
- Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
  Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., & Chang, A. L. S. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. BRITISH JOURNAL OF DERMATOLOGY, 169(3), 673–76.
- Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines
  Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Busse, P. M., Caudell, J. J., … Hughes, M. (2013). Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(8), 917–23.
- Phase 1b, Multicenter, Single Blinded, Placebo-Controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects With Locally Advanced Head and Neck Cancer Receiving Induction Chemotherapy
  Limaye, S. A., Haddad, R. I., Cilli, F., Sonis, S. T., Colevas, A. D., Brennan, M. T., … Murphy, B. A. (2013). Phase 1b, Multicenter, Single Blinded, Placebo-Controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects With Locally Advanced Head and Neck Cancer Receiving Induction Chemotherapy. CANCER, 119(24), 4268–76.
- Targeting CD137 enhances the efficacy of cetuximab.
  Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., … Levy, R. (2014). Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation, 124(6), 2668–2682.
- Targeting CD137 enhances the efficacy of cetuximab.
  Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., … Levy, R. (2014). Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation, 124(6), 2668–82.
- Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.
  Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Busse, P. M., Caudell, J. J., … Hughes, M. (2013). Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network , 11(8), 917–923.
- CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma.
  Murillo-Sauca, O., Chung, M. K., Shin, J. H., Karamboulas, C., Kwok, S., Jung, Y. H., … Sunwoo, J. B. (2014). CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma. Oncotarget, 5(16), 6854–66.
- Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
  Colevas, A. D., Lira, R. R., Colevas, E. A., Lavori, P. W., Chan, C., Shultz, D. B., & Chang, K. W. (2015). Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin. Head & Neck, 37(8), 1102–7.
- Head and Neck Cancers, Version 2.2014
  Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., … Hughes, M. (2014). Head and Neck Cancers, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(10), 1454–87.
- Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.
  Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., … Hughes, M. (2014). Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 12(10), 1454–1487.
- Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
  Tang, C., Chan, C., Jiang, W., Murphy, J. D., von Eyben, R., Colevas, A. D., … Le, Q.-T. (2015). Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head & Neck, 37(3), 386–92.
- Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients
  Gruber, J. J., & Colevas, A. D. (2015). Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients. ONCOLOGIST, 20(2), 113–26.
- Ameloblastoma: a clinical review and trends in management
  McClary, A. C., West, R. B., McClary, A. C., Pollack, J. R., Fischbein, N. J., Holsinger, C. F., … Sirjani, D. (2016). Ameloblastoma: a clinical review and trends in management. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 273(7), 1649–61.
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
  Holkova, B., Kmieciak, M., Perkins, E. B., Bose, P., Baz, R. C., Roodman, G. D., … Grant, S. (2014). Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. CLINICAL CANCER RESEARCH, 20(22), 5652–5662.
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
  Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., … Jimeno, A. (2015). A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. CLINICAL CANCER RESEARCH, 21(7), 1566–73.
- Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
  Pollom, E. L., Bui, T. T., Chang, A. L. S., Colevas, A. D., & Hara, W. Y. (2015). Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma. JAMA Dermatology, 151(9), 998–1001.
- Advances in Nanotechnology and Microfluidics for Human Papillomavirus Diagnostics
  Tasoglu, S., Tekin, H. C., Inci, F., Knowlton, S., Wang, S., Wang-Johanning, F., … Demirci, U. (2015). Advances in Nanotechnology and Microfluidics for Human Papillomavirus Diagnostics. PROCEEDINGS OF THE IEEE, 103(2), 161–78.
- Head and Neck Cancers, Version 1.2015.
  Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., … Hughes, M. (2015). Head and Neck Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network , 13(7), 847–56.
- Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN Guidelines
  Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., … Hughes, M. (2015). Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(7), 847–56.
- Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck
  Iberri, D. J., & Colevas, A. D. (2015). Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck. ONCOLOGIST, 20(12), 1393–1403.
- A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers.
  Pollom, E. L., Wang, E., Bui, T. T., Ognibene, G., von Eyben, R., Divi, V., … Hara, W. Y. (2015). A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers. Oral Oncology, 51(12), 1132–37.
- Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
  Ally, M. S., Ransohoff, K., Sarin, K., Atwood, S. X., Rezaee, M., Bailey-Healy, I., … Colevas, A. D. (2016). Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatology, 152(4), 452–56.
- Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma
  Sarin, K. Y., Ally, M. S., Ransohoff, K. J., Atwood, S. X., & Rezaee, M. (2016). Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatology, 1–5.
- Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review
  Zhu, G. A., Lira, R., & Colevas, A. D. (2016). Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review. ORAL ONCOLOGY, 53, 36–41.
- NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys
  Kurzrock, R., Colevas, A. D., Olszanski, A., Akerley, W., Arteaga, C. L., Carson, W. E., … Stewart, F. M. (2015). NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1337–46.
- Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial
  Morgan, R. J., Synold, T. W., Longmate, J. A., Quinn, D. I., Gandara, D., Lenz, H.-J., … Newman, E. M. (2015). Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 76(5), 897–907.
- Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
  Pollom, E. L., Bui, T. T., Chang, A. L. S., Colevas, A. D., & Hara, W. Y. (2015). Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma. JAMA Dermatology, 151(9), 998–1001.
- Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.
  Pan, J. J., Ng, W. T., Zong, J. F., Chan, L. L. K., O'Sullivan, B., Lin, S. J., … Lee, A. W. M. (2016). Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer, 122(4), 546–58.
- Design and rationale of a prospective multi-institutional registry for patients with sinosodal malignancy
  Beswick, D. M., Holsinger, F. C., Kaplan, M. J., Fischbein, N. J., Hara, W. Y., Colevas, A. D., … Hwang, P. H. (2016). Design and rationale of a prospective multi-institutional registry for patients with sinosodal malignancy. The Laryngoscope, ([Epub ahead of print]).
- Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy.
  Beswick, D. M., Holsinger, F. C., Kaplan, M. J., Fischbein, N. J., Hara, W., Colevas, A. D., … Hwang, P. H. (2016). Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy. Laryngoscope, 126(9), 1977–80.
- Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas
  Roberts, T. J., Colevas, A. D., Hara, W., Holsinger, F. C., Oakley-Girvan, I., & Divi, V. (2016). Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas. CANCER, 122(9), 1388–97.
- BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response
  Tan, S., Pollack, J. R., Kaplan, M. J., Colevas, A. D., & West, R. B. (2016). BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 122(1), E5–E7.
- Third party assessment of resection margin status in head and neck cancer.
  Ransohoff, A., Wood, D., Solomon Henry, A., Divi, V., & Colevas, A. (2016). Third party assessment of resection margin status in head and neck cancer. Oral Oncology, 57, 27–31.
- Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer
  Narayanan, S., & Colevas, A. D. (2016). Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 17(6).
- A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
  Rosen, L. S., LoRusso, P., Ma, W. W., Goldman, J. W., Weise, A., Colevas, A. D., … Sikic, B. I. (2016). A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Investigational New Drugs, 34(5), 604–13.
- Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence
  Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., … Yao, M. (2013). Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. CANCER, 119(7), 1349–56.
- Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer
  Tang, C., Murphy, J. D., Khong, B., La, T. H., Kong, C., Fischbein, N. J., … Quynh-Thu Le, Q. T. (2012). Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(5), 1514–20.
- Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.
  Pan, J. J., Ng, W. T., Zong, J. F., Lee, S. W. M., Choi, H. C. W., Chan, L. L. K., … Lee, A. W. M. (2016). Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer, 122(21), 3307–15.
- Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
  Tran, D. C., Colevas, A. D., & Chang, A. L. S. (2016). Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma. JAMA Dermatology.
- Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.
  Freites-Martinez, A., Kwong, B. Y., Rieger, K. E., Coit, D. G., Colevas, A. D., & Lacouture, M. E. (2017). Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy. JAMA Dermatology.
- Characterizing CD137 Upregulation on NK cells in Patients Receiving Monoclonal Antibody Therapy.
  MAKKOUK, A., Sundaram, V., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., … Kohrt, H. E. (2016). Characterizing CD137 Upregulation on NK cells in Patients Receiving Monoclonal Antibody Therapy. Annals of Oncology .
- Third party assessment of resection margin status in head and neck cancer
  Ransohoff, A., Wood, D., Henry, A. S., Divi, V., & Colevas, A. (2016). Third party assessment of resection margin status in head and neck cancer. ORAL ONCOLOGY, 57, 27–31.
- Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.
  Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., … Divi, V. (2017). Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head & Neck.
- E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
  Marur, S., Li, S., Cmelak, A. J., Gillison, M. L., Zhao, W. J., Ferris, R. L., … Burtness, B. (2016). E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology , JCO2016683300-?
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
  Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Gillison, M. L. (2016). Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. NEW ENGLAND JOURNAL OF MEDICINE, 375(19), 1856–67.
- Transsphenoidal Resection of Sellar Tumors Using High-Field Intraoperative Magnetic Resonance Imaging
  Szerlip, N. J., Zhang, Y.-C., Placantonakis, D. G., Goldman, M., Colevas, K. B., Rubin, D. G., … Tabar, V. (2011). Transsphenoidal Resection of Sellar Tumors Using High-Field Intraoperative Magnetic Resonance Imaging. SKULL BASE-AN INTERDISCIPLINARY APPROACH, 21(4), 223–32.
- Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone
  Mani, S., McDaid, H. M., Grossman, A., Muggia, F., Goel, S., Griffin, T., … Egorin, M. J. (2007). Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. ANNALS OF ONCOLOGY, 18(1), 190–95.
- Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 213 design
  Gadgeel, S. M., Wozniak, A., Boinpally, R. R., Wiegand, R., Heilbrun, L. K., Jain, V., … LoRusso, P. M. (2005). Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 213 design. CLINICAL CANCER RESEARCH, 11(17), 6233–39.
- Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy
  MAKKOUK, A., Sundaram, V., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., … Kohrt, H. E. (2017). Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. ANNALS OF ONCOLOGY, 28(2), 415–20.
- E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx-ECOG-ACRIN Cancer Research Group
  Marur, S., Li, S., Cmelak, A. J., Gillison, M. L., Zhao, W. J., Ferris, R. L., … Burtness, B. (2017). E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx-ECOG-ACRIN Cancer Research Group. AMERICAN JOURNAL OF PSYCHOLOGY, 130(1), 490–U169.
- Comparative Effectiveness of Cetuximab or Cisplatin With Concomitant Radiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Analysis
  Xiang, M., Holsinger, F. C., Chen, M. M., Colevas, A. D., & Beadle, B. M. (2018). Comparative Effectiveness of Cetuximab or Cisplatin With Concomitant Radiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(5), 1322.
- Panitumumab-IRDye800 as an Optical Agent for Image-Guided Surgery in Patients With Squamous Cell Carcinoma
  Gao, R. W., Teraphongphom, N., van den Berg, N. S., Hong, S., Martin, B. A., Divi, V., … Rosenthal, E. L. (2018). Panitumumab-IRDye800 as an Optical Agent for Image-Guided Surgery in Patients With Squamous Cell Carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(5), 1312–13.
- Survival Benefit of Postoperative Chemotherapy for Intermediate-Risk Advanced Stage Head and Neck Cancer
  Chen, M. M., Colevas, A. D., Megwalu, U., & Divi, V. (2018). Survival Benefit of Postoperative Chemotherapy for Intermediate-Risk Advanced Stage Head and Neck Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(5), 1326.
- Postoperative Radiation Therapy for Minor Salivary Gland Carcinomas of the Head and Neck: Long-term Outcomes
  Zeidan, Y., Murphy, J. D., Chan, C., An, Y., Kaplan, M., Colevas, A., … Le, Q. (2012). Postoperative Radiation Therapy for Minor Salivary Gland Carcinomas of the Head and Neck: Long-term Outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S500.
- Intensity modulated radiotherapy for squamous cell carcinoma of the hypopharynx and larynx: Clinical outcomes and patterns of failure
  Daly, M. E., Le, Q. T., Loo, B. W., Maxim, P. G., Pinto, H. A., Colevas, A. D., … Chang, D. T. (2008). Intensity modulated radiotherapy for squamous cell carcinoma of the hypopharynx and larynx: Clinical outcomes and patterns of failure. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S405–S406.
- Regionally Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck: Survival and High-Risk Features
  Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., … Divi, V. (2016). Regionally Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck: Survival and High-Risk Features. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- A Pilot Study of Electronic Quality of Life Assessments Using Tablet Devices During and After Treatment of Head and Neck Cancers
  Wang, E., Pollom, E., Bui, T., Ognibene, G., von Eyben, R., Divi, V., … Hara, W. (2016). A Pilot Study of Electronic Quality of Life Assessments Using Tablet Devices During and After Treatment of Head and Neck Cancers. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 94(4), 969.
- A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors
  Rosen, L., LoRusso, P., Ma, W. W., Goldman, J., Weise, A., Colevas, A. D., … Sikic, B. (2011). A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. CANCER RESEARCH, 71.
- Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
  Gao, R. W., Teraphongphom, N., de Boer, E., van den Berg, N. S., Divi, V., Kaplan, M. J., … Rosenthal, E. L. (2018). Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. THERANOSTICS, 8(9), 2488–95.
- NCCN Guidelines (R) Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines
  Colevas, A. D., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., … Darlow, S. D. (2018). NCCN Guidelines (R) Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(5), 479–90.
- A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy
  Gubens, M. A., Chuang, J. C., Akerley, W., Langer, C. J., Clement-Duchene, C., San Pedro-Salcedo, M., … Wakelee, H. A. (2018). A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. JOURNAL OF THORACIC DISEASE, 10(1), 219–27.
- Comparative Effectiveness and Toxicity of Cetuximab or Cisplatin With Concurrent Radiation for Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck: A Population-Based Analysis
  Xiang, M., Holsinger, F. C., Chen, M., Colevas, A. D., & Beadle, B. M. (2018). Comparative Effectiveness and Toxicity of Cetuximab or Cisplatin With Concurrent Radiation for Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck: A Population-Based Analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups
  Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Gillison, M. (2018). Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(5), 1317.
- Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504
  Gillison, M., Ferris, R. L., Zhang, Q., Colevas, A. D., Mell, L. K., Kirsch, C., … Le, Q. T. (2018). Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(5), 1307–8.
- Nivolumab (Nivo) vs Investigator's Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141): Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy
  Kasper, S., Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., … Ferris, R. L. (2018). Nivolumab (Nivo) vs Investigator's Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141): Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy. ONCOLOGY RESEARCH AND TREATMENT, 41, 96.
- Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
  Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Gillison, M. L. (2018). Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. ORAL ONCOLOGY, 81, 45–51.
- Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence.
  Gao, R. W., Teraphongphom, N. T., van den Berg, N. S., Martin, B. A., Oberhelman, N. J., Divi, V., … Rosenthal, E. L. (2018). Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence. Cancer Research.
- Review of pathologic diagnosis in head and neck cancer patients: Why do it?
  Zhu, G. A., Lira, R. R., & Colevas, A. D. (2014). Review of pathologic diagnosis in head and neck cancer patients: Why do it? JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.
  Sikic, B. I., Eckhardt, S. G., Gallant, G., Burris, H. A., Camidge, D. R., Colevas, A. D., … Infante, J. R. (2011). Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
- A POOLED ANALYSIS OF ADVANCED NONSQUAMOUS NSCLC PATIENTS WITH STABLE TREATED BRAIN METASTASES IN TWO PHASE II TRIALS RECEIVING BEVACIZUMAB AND PEMETREXED AS SECOND-LINE THERAPY
  Gubens, M., Akerley, W., Lynch, T., Langer, C. J., Socinski, M. A., Colevas, A. D., … Wakelee, H. (2011). A POOLED ANALYSIS OF ADVANCED NONSQUAMOUS NSCLC PATIENTS WITH STABLE TREATED BRAIN METASTASES IN TWO PHASE II TRIALS RECEIVING BEVACIZUMAB AND PEMETREXED AS SECOND-LINE THERAPY. JOURNAL OF THORACIC ONCOLOGY, 6(6), S1224–S1225.
- Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.
  Eckhardt, S. G., Gallant, G., Sikic, B. I., Camidge, D. R., Burris, H. A., Wakelee, H. A., … Infante, J. R. (2010). Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
- NCCN Guidelines (R) Insights Head and Neck Cancers, Version 2.2017
  Adelstein, D., Gillison, M. L., Pfister, D. G., Spencer, S., Adkins, D., Brizel, D. M., … Darlow, S. D. (2017). NCCN Guidelines (R) Insights Head and Neck Cancers, Version 2.2017. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(6), 761–70.
- PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
  Amoils, M., Kim, J., Lee, C., Sunwoo, J. B., Colevas, A. D., Aasi, S. Z., … Divi, A. V. (2018). PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, 194599818788057.
- BRAF inhibitor therapy of primary ameloblastoma
  Tan, S., Pollack, J. R., Kaplan, M. J., Colevas, A. D., & West, R. B. (2016). BRAF inhibitor therapy of primary ameloblastoma. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 122(4), 518–19.
- Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
  Trieu, V., Pinto, H., Riess, J. W., Lira, R., Luciano, R., Coty, J., … Colevas, A. D. (2018). Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. ONCOLOGIST, 23(7), 764-+.
- A case of combination PD-1 inhibitor and intralesional 5-fluorouracil for high-frequency nonmelanoma skin cancers in an immunocompromised patient
  Duy Tran, Lee, C., Colevas, A. D., & Chang, A. L. (2018). A case of combination PD-1 inhibitor and intralesional 5-fluorouracil for high-frequency nonmelanoma skin cancers in an immunocompromised patient. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. MOSBY-ELSEVIER.
- Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age
  Chen, M. M., Colevas, A. D., Megwalu, U., & Divi, V. (2018). Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age. ORAL ONCOLOGY, 84, 71–75.
- Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.
  Chang, A. L., Tran, D. C., Cannon, J. G., Li, S., Jeng, M., Patel, R., … Colevas, A. D. (2018). Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. Journal of the American Academy of Dermatology.
- Safety and Clinical Activity of Atezolizumab in Head and Neck Cancer: Results From a Phase I Trial.
  Colevas, A. D., Bahleda, R., Braiteh, F., Balmanoukian, A., Brana, I., Chau, N. G., … Powderly, J. (2018). Safety and Clinical Activity of Atezolizumab in Head and Neck Cancer: Results From a Phase I Trial. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
  Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Ferris, R. L. (2018). CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. ONCOLOGIST, 23(9), 1079–82.
- Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
  Xiang, M., Holsinger, F. C., Colevas, A. D., Chen, M. M., Le, Q.-T., & Beadle, B. M. (2018). Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer.
- Outcomes of elderly patients treated for oral cavity squamous cell carcinoma
  Shah, J. L., Kaplan, M., Colevas, A. D., Quynh-Thu Le, & Hara, W. (2015). Outcomes of elderly patients treated for oral cavity squamous cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma
  Bui, T., Shah, J. L., Kaplan, M., Colevas, A. D., Quynh-Thu Le, & Hara, W. (2015). Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
  Chen, Y.-P., Wang, Y.-Q., Lv, J.-W., Li, Y.-Q., Chua, M. L., Le, Q.-T., … Ma, J. (2018). Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
  Gillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein, D. J., … Le, Q. T. (2018). Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet (London, England).
- Cisplatin or Carboplatin-Based Chemoradiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Comparison
  Xiang, M., Holsinger, F. C., Colevas, A. D., Hara, W., Le, Q. T., & Beadle, B. M. (2018). Cisplatin or Carboplatin-Based Chemoradiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Comparison. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(3), E371.
- Cost comparison of treatment for oropharyngeal carcinoma.
  Tam, K., Orosco, R. K., Dimitrios Colevas, A., Bedi, N., Starmer, H. M., Beadle, B. M., & Christopher Holsinger, F. (2018). Cost comparison of treatment for oropharyngeal carcinoma. The Laryngoscope.
- NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx
  Trotti, A., Harris, J., Gillison, M., Eisbruch, A., Harari, P. M., Adelstein, D. J., … Le, Q. T. (2018). NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(5), 1604–5.
- Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma.
  van Keulen, S., van den Berg, N. S., Nishio, N., Birkeland, A., Zhou, Q., Lu, G., … Rosenthal, E. L. (2019). Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma. Oral Oncology, 88, 58–65.
- The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer.
  van Keulen, S., Nishio, N., Fakurnejad, S., Birkeland, A., Martin, B. A., Lu, G., … Rosenthal, E. L. (2019). The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine.
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
  Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1802018.
- Hearing evaluation of head and neck cancer patients (HNCP): Comparison of adverse event (AE) criteria
  Colevas, A. D., Lira, R. R., Colevas, E. A., Lavori, P. W., & Chang, K. W. (2012). Hearing evaluation of head and neck cancer patients (HNCP): Comparison of adverse event (AE) criteria. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- High incidence of larynx cancers in Vietnamese population in the bay area
  Huang, D. D., Filion, E. J., Chang, E., Colevas, A. D., Kaplan, M. J., & Le, Q. (2008). High incidence of larynx cancers in Vietnamese population in the bay area. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S484.
- A phase 2 trial of flavopiridol and cisplatin in platinum-resistant ovarian cancer
  Peethambaram, P. P., Burton, J. K., Oberg, A. L., Gomez-Dahl, L. C., Isham, C. R., Tibodeau, J. D., … Bible, K. C. (2007). A phase 2 trial of flavopiridol and cisplatin in platinum-resistant ovarian cancer. MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH.
- Nivolumab vs Investigator'S Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
  Ferris, R. L., Licitra, L., Fayette, J., Even, C., Blumenschein, G., Harrington, K. J., … Gillison, M. L. (2017). Nivolumab vs Investigator'S Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
- Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy
  Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Ferris, R. L. (2017). Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 13, 144.
- Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  Concha-Benavente, F., Gillison, M. L., Blumenschien, G., Harrington, K. J., Fayette, J., Colevas, A. D., … Ferris, R. L. (2017). Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN). ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 13, 141.
- Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes
  Haddad, R., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Ferris, R. L. (2017). Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes. ANNALS OF ONCOLOGY, 28.
- Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase la Trial Results
  Bahleda, R., Braiteh, F. S., Balmanoukian, A. S., Brana, I., Hodi, F. S., Garbo, L., … Colevas, A. D. (2017). Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase la Trial Results. ANNALS OF ONCOLOGY, 28.
- Treatment beyond progression with nivolumab (nivo) in patients with recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the phase 3 CheckMate 141 study
  Kasper, S., Haddad, R., Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., … Harrington, K. J. (2017). Treatment beyond progression with nivolumab (nivo) in patients with recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the phase 3 CheckMate 141 study. ONCOLOGY RESEARCH AND TREATMENT, 40, 250-+.
- Commentary on "Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data"
  Colevas, A. D. (2017). Commentary on "Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data". ONCOLOGIST, 22(9), 1022–23.
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
  Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A. D., Fayette, J., Licitra, L., … Guigay, J. (2017). Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. LANCET ONCOLOGY, 18(8), 1104–15.
- PD-1 inhibition for cutaneous squamous cell carcinoma: A study of six consecutive cases
  Duy Tran, Colevas, A. D., & Chang, A. (2017). PD-1 inhibition for cutaneous squamous cell carcinoma: A study of six consecutive cases. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 76(6), AB193.
- Outcomes of Young Patients With Oral Cavity Squamous Cell Carcinoma
  Shah, J. L., Bui, T., Kaplan, M., Colevas, A. D., Le, Q. T., & Hara, W. (2015). Outcomes of Young Patients With Oral Cavity Squamous Cell Carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93(3), S214.
- Prognostic Value of Lymph Node Status Is Greater Than Lymph Node Ratio and AJCC N Staging for Head and Neck Squamous Cell Carcinomas
  Roberts, T., Colevas, A. D., Hara, W., Holsinger, F. C., Oakley-Girvan, I., & Divi, V. (2016). Prognostic Value of Lymph Node Status Is Greater Than Lymph Node Ratio and AJCC N Staging for Head and Neck Squamous Cell Carcinomas. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor
  Chang, A. L. S., Kim, J., Luciano, R., Sullivan-Chang, L., & Colevas, A. D. (2016). A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor. JAMA DERMATOLOGY, 152(1), 106–8.
- New Diseases and New Treatments-Head and Neck Cancer Updates Preface
  Colevas, A. D. (2015). New Diseases and New Treatments-Head and Neck Cancer Updates Preface. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 29(6), XIII-XIV.
- E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
  Cmelak, A., Li, S., Marur, S., Zhao, W., Westra, W. H., Chung, C. H., … Burtriess, B. (2014). E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). JOURNAL OF CLINICAL ONCOLOGY, 32(18).
- E1308: Reduced-dose INERT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
  Cmelak, A., Li, S., Marur, S., Zhao, W., Westra, W. H., Chung, C. H., … Burtness, B. (2014). E1308: Reduced-dose INERT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- Third party assessment of resection margin status in head and neck cancer.
  Ransohoff, A., Wood, D., Henry, S., Divi, V., & Colevas, A. D. (2015). Third party assessment of resection margin status in head and neck cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Evaluation of patients with disseminated or locoregionally advanced thyroid cancer: a primer for medical oncologists.
  Colevas, A. D., & Shah, M. H. (2012). Evaluation of patients with disseminated or locoregionally advanced thyroid cancer: a primer for medical oncologists. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 384–88.
- E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC)
  Marur, S., Li, S., Cmelak, A., Gillison, M. L., Ferris, R. L., Bauman, J. E., … Colevas, A. D. (2013). E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). JOURNAL OF CLINICAL ONCOLOGY, 31(15).
- Chemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxia imaging with F18 misonidazole PET scanning.
  Colevas, A. D., Quon, A., McMillan, A., & Le, Q. (2011). Chemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxia imaging with F18 misonidazole PET scanning. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
- A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity
  Colevas, A. D., Clarke, C. A., Lichtensztajn, D., & Chang, E. T. (2010). A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
- Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP)
  Cao, H., Kwok, S., Shi, X., Bala, R., Pinsky, B., Colevas, A. D., … Le, Q. (2010). Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP). JOURNAL OF CLINICAL ONCOLOGY, 28(15).
- Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors
  Fan, A. C., Dermody, J., Kong, C., Zhang, N., Colevas, A. D., & Felsher, D. W. (2010). Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
- A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer
  He, A. R., Kunz, P. L., Pishvaian, M. J., Colevas, A. D., Hwang, J. J., Clemens, P. L., … Sikic, B. I. (2010). A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
- Toxicity Monitoring: Why, What, When.?
  Colevas, A. D. (2010). Toxicity Monitoring: Why, What, When.? ONCOLOGY CLINICAL TRIALS, 151–61.
- Intensity Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure
  Wiegner, E. A., Daly, M. E., Chapman, C. H., Yu, Y., Colevas, A. D., Kaplan, M. J., … Chang, D. T. (2010). Intensity Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S463.
- Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms
  Grant, S., Sullivan, D., Roodman, D., Stuart, R. K., Perkins, E., Kolla, S., … Roberts, J. D. (2008). Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms. BLOOD. AMER SOC HEMATOLOGY.
- Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.
  Thu Le, Q., Dimitrios Colevas, A., O'Sullivan, B., Lee, A. W., Lee, N., Ma, B., … Malik, S. (2019). Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. Journal of the National Cancer Institute.
- Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review.
  Zhu, G. A., Lira, R., & Colevas, A. D. (2016). Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review. Oral Oncology, 53, 36–41.
- Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.
  Iberri, D. J., & Colevas, A. D. (2015). Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck. The Oncologist.
- PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma
  Amoils, M., Kim, J., Lee, C., Sunwoo, J. B., Colevas, A. D., Aasi, S. Z., … Divi, V. (2019). PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 160(1), 93–99.
- Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
  Nishio, N., van den Berg, N. S., van Keulen, S., Martin, B. A., Fakurnejad, S., Zhou, Q., … Rosenthal, E. L. (2019). Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer. Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging.
- Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence
  Gao, R. W., Teraphongphom, N. T., van den Berg, N. S., Martin, B. A., Oberhelman, N. J., Divi, V., … Rosenthal, E. L. (2018). Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence. CANCER RESEARCH, 78(17), 5144–54.
- Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis
  Xiang, M., Holsinger, F. C., Colevas, A. D., Chen, M. M., Quynh-Thu Le, & Beadle, B. M. (2018). Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis. CANCER, 124(23), 4486–94.
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
  Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(12), 946-+.
- Pembrolizumab with or without vismodegib for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study
  Chang, A., Tran, D. C., Cannon, J., Li, S., Jeng, M., Rieger, K., … Colevas, A. (2019). Pembrolizumab with or without vismodegib for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 139(5), S92.
- Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma
  van Keulen, S., van den Berg, N. S., Nishio, N., Birkeland, A., Zhou, Q., Lu, G., … Rosenthal, E. L. (2019). Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma. ORAL ONCOLOGY, 88, 58–65.
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
  Gillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein, D. J., … Quynh Thu Le. (2019). Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. LANCET, 393(10166), 40–50.
- Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
  Chen, Y.-P., Wang, Y.-Q., Lv, J.-W., Li, Y.-Q., Chua, M. L. K., Le, Q.-T., … Ma, J. (2019). Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. ANNALS OF ONCOLOGY, 30(1), 68–75.
- Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).
  Ferris, R. L., Concha-Benavente, F., Blumenschein, G. R., Harrington, K. J., Fayette, J., Colevas, A. D., … Vokes, E. E. (2017). Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN). JOURNAL OF CLINICAL ONCOLOGY, 35(7).
- Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study
  Chang, A. L. S., Tran, D. C., Cannon, J. G. D., Li, S., Jeng, M., Patel, R., … Colevas, A. D. (2019). Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 80(2), 564–66.
- A randomized phase II study of chemoradiation (CRT) plus /- nivolumab (Nivo) with sequential safety evaluations of Nivo plus /- lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RI in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).
  Gillison, M. L., Ferris, R. L., Zhang, Q., Colevas, A. D., Mell, L. K., Kong, C., … Le, Q.-T. (2017). A randomized phase II study of chemoradiation (CRT) plus /- nivolumab (Nivo) with sequential safety evaluations of Nivo plus /- lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RI in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593). JOURNAL OF CLINICAL ONCOLOGY, 35.
- The Sentinel Margin: Intraoperative ex-vivo Specimen Mapping Using Relative Fluorescence Intensity.
  van Keulen, S., Nishio, N., Birkeland, A., Fakurnejad, S., Martin, B. A., Forouzanfar, T., … Rosenthal, E. L. (2019). The Sentinel Margin: Intraoperative ex-vivo Specimen Mapping Using Relative Fluorescence Intensity. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141
  Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Gillison, M. L. (2018). Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. CANCER RESEARCH, 78(13).
- The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer
  van Keulen, S., Nishio, N., Fakurnejad, S., Birkeland, A., Martin, B. A., Lu, G., … Rosenthal, E. L. (2019). The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer. JOURNAL OF NUCLEAR MEDICINE, 60(6), 758–63.
- An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.
  Sacco, A. G., Messer, K., Leidner, R. S., Colevas, A. D., Nieva, J. J., Chau, N. G., … Cohen, E. E. W. (2017). An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 35.
- Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).
  Concha-Benavente, F., Gillison, M. L., Blumenschein, G. R., Harrington, K., Fayette, J., Colevas, A. D., … Ferris, R. L. (2017). Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN). JOURNAL OF CLINICAL ONCOLOGY, 35.
- Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.
  Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L. F., … Gillison, M. L. (2016). Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
- Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
  Haddad, R., Concha-Benavente, F., Blumenschein, G. J., Fayette, J., Guigay, J., Colevas, A. D., … Ferris, R. L. (2019). Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer.
- Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
  Ferris, R. L., Licitra, L., Fayette, J., Even, C., Blumenschein, G. R., Harrington, K. J., … Gillison, M. L. (2019). Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Development and validation of radiomic signatures of head and neck squamous cell carcinoma molecular features and subtypes.
  Huang, C., Cintra, M., Brennan, K., Zhou, M., Colevas, A. D., Fischbein, N., … Gevaert, O. (2019). Development and validation of radiomic signatures of head and neck squamous cell carcinoma molecular features and subtypes. EBioMedicine.
- Cost comparison of treatment for oropharyngeal carcinoma
  Tam, K., Orosco, R. K., Colevas, A. D., Bedi, N., Starmer, H. M., Beadle, B. M., & Holsinger, F. C. (2019). Cost comparison of treatment for oropharyngeal carcinoma. LARYNGOSCOPE, 129(7), 1604–9.
- A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers
  Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2016). A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
  Rischin, D., Boyer, M. J., Brzezniak, C. E., Colevas, A. D., Doebele, R. C., Gilbert, J., … Liu, S. V. (2016). A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). JOURNAL OF CLINICAL ONCOLOGY, 34(15).
- Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer.
  Fakurnejad, S., van Keulen, S., Nishio, N., Engelen, M., van den Berg, N. S., Lu, G., … Martin, B. A. (2019). Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer. Oral Oncology, 97, 50–55.
- Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
  Xiang, M., Colevas, A. D., Holsinger, F. C., Le, Q.-T. X., & Beadle, B. M. (2019). Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 17(9), 1065–73.
- Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy
  Le, Q. T., Colevas, A. D., OSullivan, B., Lee, A. W. M., Lee, N., Ma, B., … Malik, S. (2019). Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 111(7), 655–63.
- Intraoperative Tumor Assessment Using Real-Time Molecular Imaging in Head and Neck Cancer Patients.
  Keulen, S. van, Nishio, N., Fakurnejad, S., van den Berg, N. S., Lu, G., Birkeland, A., … Rosenthal, E. L. (2019). Intraoperative Tumor Assessment Using Real-Time Molecular Imaging in Head and Neck Cancer Patients. Journal of the American College of Surgeons.
- Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment.
  Nishio, N., van Keulen, S., van den Berg, N. S., Lu, G., LaRochelle, E. P., Davis, S. C., … Rosenthal, E. L. (2019). Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment. Head & Neck.
- Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.
  Gillison, M. L., Ferris, R. L., Harris, J., Colevas, A. D., Mell, L. K., Kong, C., … Quynh-Thu Le. (2019). Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV plus NPC).
  Siu, L. L., Bauml, J., Adkins, D., Colevas, A. D., Perez, C. A., Choe, J. H., … Pfister, D. G. (2019). Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV plus NPC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.
  Saraswathula, A., Chen, M. M., Colevas, A. D., & Divi, V. (2019). Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer. JAMA Otolaryngology-- Head & Neck Surgery.
- Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer.
  Nishio, N., van den Berg, N. S., van Keulen, S., Martin, B. A., Fakurnejad, S., Teraphongphom, N., … Rosenthal, E. L. (2019). Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer. Nature Communications, 10(1), 5044.
- Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.
  Nambiar, D. K., Aguilera, T., Cao, H., Kwok, S., Kong, C., Bloomstein, J., … Le, Q. T. (2019). Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. The Journal of Clinical Investigation.
- Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers.
  Lu, G., Fakurnejad, S., Martin, B. A., van den Berg, N. S., van Keulen, S., Nishio, N., … Rosenthal, E. L. (2020). Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Intraoperative Molecular Imaging for ex vivo Assessment of Peripheral Margins in Oral Squamous Cell Carcinoma.
  Fakurnejad, S., Krishnan, G., van Keulen, S., Nishio, N., Birkeland, A. C., Baik, F. M., … Martin, B. A. (2019). Intraoperative Molecular Imaging for ex vivo Assessment of Peripheral Margins in Oral Squamous Cell Carcinoma. Frontiers in Oncology, 9, 1476.
- Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer
  Nishio, N., van den Berg, N. S., van Keulen, S., Martin, B. A., Fakurnejad, S., Zhou, Q., … Rosenthal, E. L. (2020). Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer. MOLECULAR IMAGING AND BIOLOGY, 22(1), 156–64.
- Exome scale liquid biopsy monitoring of putative neoantigens and genomic biomarkers in patients on anti-PD-1 therapy in squamous cell carcinoma of the head and neck.
  Abbott, C. W., Bedi, N., Zhang, S. V., Li, R., Pyke, R. M., Levy, E., … Boyle, S. M. (2020). Exome scale liquid biopsy monitoring of putative neoantigens and genomic biomarkers in patients on anti-PD-1 therapy in squamous cell carcinoma of the head and neck. CANCER IMMUNOLOGY RESEARCH. AMER ASSOC CANCER RESEARCH.
- A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
  Sikic, B. I., Lakhani, N. J., Patnaik, A., Shah, S., Chandana, S. R., Rasco, D. W., … Padda, S. K. (2018). A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- CT-based Radiomic Signatures for Predicting Histopathologic Features in Head and Neck Squamous Cell Carcinoma.
  Mukherjee, P., Cintra, M., Huang, C., Zhou, M., Zhu, S., Colevas, A. D., … Gevaert, O. (2020). CT-based Radiomic Signatures for Predicting Histopathologic Features in Head and Neck Squamous Cell Carcinoma. Radiology. Imaging Cancer, 2(3), e190039.
- Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial
  Ridge, J. A., Ringash, J., Yao, M., Blakaj, D. M., Razaq, M. A., Colevas, A. D., … Burtness, B. (2020). Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Intraoperative Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma
  Lee, Y.-J., Krishnan, G., Nishio, N., van den Berg, N. S., Lu, G., Martin, B. A., … Rosenthal, E. L. (2020). Intraoperative Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma. LARYNGOSCOPE.
- Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.
  Ferris, R. L., Gillison, M. L., Harris, J., Colevas, A. D., Mell, L. K., Kong, C., … Le, Q.-T. (2018). Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Safety and Stability of Antibody-Dye Conjugate in Optical Molecular Imaging.
  Pei, J., Juniper, G., van den Berg, N. S., Nisho, N., Broadt, T., Welch, A. R., … Rosenthal, E. L. (2020). Safety and Stability of Antibody-Dye Conjugate in Optical Molecular Imaging. Molecular Imaging and Biology.
- Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma.
  Marukian, N. V., Lin, J. Q., Colevas, A. D., Coutre, S., & Chang, A. L. (2020). Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. JAAD Case Reports, 6(9), 819–21.
- Association Between Immunosuppression and Outcomes in Oral Cavity Squamous Cell Carcinoma.
  Chang, J., Sunwoo, J. B., Shah, J. L., Hara, W., Hong, J., Colevas, A. D., & Divi, V. (2020). Association Between Immunosuppression and Outcomes in Oral Cavity Squamous Cell Carcinoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, 194599820960146.
- Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck.
  Abbott, C., Bedi, N., Zhang, S., Li, R., Pyke, R., Levy, E., … Boyle, S. M. (2020). Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Head and Neck Cancers, Version 2.2020
  Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Anzai, Y., Brizel, D. M., … Darlow, S. D. (2020). Head and Neck Cancers, Version 2.2020. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 18(7), 873–98.
- Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates.
  Lu, G., Nishio, N., van den Berg, N. S., Martin, B. A., Fakurnejad, S., van Keulen, S., … Rosenthal, E. L. (2020). Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates. Nature Communications, 11(1), 5667.
- Survival Benefit of Postoperative Radiotherapy in Pathological N1 Oral Cavity Squamous Cell Carcinoma
  Xiang, M., Holsinger, F. C., Gensheimer, M. F., Divi, V., Pollom, E., Colevas, A. D., … Beadle, B. M. (2020). Survival Benefit of Postoperative Radiotherapy in Pathological N1 Oral Cavity Squamous Cell Carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Treatment Breaks During Definitive Head/Neck Radiotherapy: Survival Impact and Predisposing Factors
  Xiang, M., Gensheimer, M., Pollom, E., Holsinger, F. C., Colevas, A. D., Quynh-Thu Le, & Beadle, B. (2020). Treatment Breaks During Definitive Head/Neck Radiotherapy: Survival Impact and Predisposing Factors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors.
  Xiang, M., Gensheimer, M. F., Pollom, E. L., Holsinger, F. C., Colevas, A. D., Le, Q.-T. T., & Beadle, B. M. (2020). Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology.
- Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.
  Chen, Y.-P., Ismaila, N., Chua, M. L., Colevas, A. D., Haddad, R., Huang, S. H., … Ma, J. (2021). Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2003237.
- Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma.
  Xiang, M., Holsinger, F. C., Gensheimer, M. F., Divi, V., Pollom, E. L., Colevas, A. D., … Beadle, B. M. (2021). Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma. American Journal of Clinical Oncology, Publish Ahead of Print.
- Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems.
  Mao, Y., Wang, S., Lydiatt, W., Shah, J. P., Colevas, A. D., Lee, A. W., … Ma, J. (2021). Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology.
- Intraoperative Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma.
  Lee, Y.-J. J., Krishnan, G., Nishio, N., van den Berg, N. S., Lu, G., Martin, B. A., … Rosenthal, E. L. (2021). Intraoperative Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma. The Laryngoscope, 131(3), 529–534.
- Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy
  Pyke, R. M., Abbott, C., Mellacheruvu, D., Zhang, S., Bedi, N., Colevas, A. D., … Boyle, S. M. (2020). Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
  Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39.
- Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW
  Krishnan, G., van den Berg, N. S., Nishio, N., Juniper, G., Pei, J., Zhou, Q., … Rosenthal, E. L. (2021). Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW. THERANOSTICS, 11(15), 7188–7198.
- Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW.
  Krishnan, G., van den Berg, N. S., Nishio, N., Juniper, G., Pei, J., Zhou, Q., … Rosenthal, E. L. (2021). Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW. Theranostics, 11(15), 7188–7198.
- Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
  Lansinger, O. M., Biedermann, S., He, Z., & Colevas, A. D. (2021). Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2101200.
- Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm.
  Pyke, R. M., Mellacheruvu, D., Abbott, C., Dea, S., Levy, E., Zhang, S. V., … Boyle, S. M. (2021). Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy.
  Abbott, C. W., Bedi, N., Zhang, S. V., Northcott, J., Li, R., Pyke, R. M., … Chen, R. (2021). Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
  Haydon, A. M., Alamgeer, M., Brungs, D., Collichio, F., Khushalani, N. I., Colevas, A. D., … Hill, A. (2021). A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]. ANNALS OF ONCOLOGY. ELSEVIER.
- Post-Treatment FDG-PET/CT Hopkins Criteria Predict Locoregional Recurrence After Definitive Radiotherapy for Oropharyngeal Squamous Cell Carcinoma.
  Miller, J. A., Moradi, F., Liang, R., Zhang, C., Nguyen, N., Akhtar, F., … Gensheimer, M. F. (2021). Post-Treatment FDG-PET/CT Hopkins Criteria Predict Locoregional Recurrence After Definitive Radiotherapy for Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e399.
- Genome Sequencing and Apoptotic Markers to Assess Treatment Response of Lacrimal Gland Adenoid Cystic Carcinoma to Intra-Arterial Cytoreductive Chemotherapy.
  Yu, M. D., Men, C. J., Do, H., Colevas, A. D., Lin, J. H., Egbert, P. R., … Kossler, A. L. (2021). Genome Sequencing and Apoptotic Markers to Assess Treatment Response of Lacrimal Gland Adenoid Cystic Carcinoma to Intra-Arterial Cytoreductive Chemotherapy. Ophthalmic Plastic and Reconstructive Surgery.
- Post-Treatment FDG-PET/CT Hopkins Criteria Predict Locoregional Recurrence After Definitive Radiotherapy for Oropharyngeal Squamous Cell Carcinoma
  Miller, J. A., Moradi, F., Liang, R., Zhang, C., Nguyen, N., Akhtar, F., … Gensheimer, M. F. (2021). Post-Treatment FDG-PET/CT Hopkins Criteria Predict Locoregional Recurrence After Definitive Radiotherapy for Oropharyngeal Squamous Cell Carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Association of HLA loss of heterozygosity with allele-specific neoantigen expansion in response to immunotherapy.
  Pyke, R. M., Abbott, C., Dea, S., Bedi, N., Colevas, A. D., Levy, E., … Boyle, S. M. (2021). Association of HLA loss of heterozygosity with allele-specific neoantigen expansion in response to immunotherapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Treatment patterns for patients with metastatic or recurrent head and neck cancer in a large integrated health-care system.
  Seto, T., Samant, N. D., Shah, N., Shirazi, A., Colevas, A. D., & Katzel, J. A. (2021). Treatment patterns for patients with metastatic or recurrent head and neck cancer in a large integrated health-care system. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Skull base osteomyelitis in patients with head and neck cancer: Diagnosis, management, and outcomes in a case series of 23 patients
  Czech, M. M., Hwang, P. H., Colevas, A. D., Fischbein, N., & Ho, D. Y. (2022). Skull base osteomyelitis in patients with head and neck cancer: Diagnosis, management, and outcomes in a case series of 23 patients. LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY.
- Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.
  Shukla, N. D., Chiang, R. S., & Colevas, A. D. (2022). Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan. Journal of the National Comprehensive Cancer Network : JNCCN, 20(2), 102–104.
- Skull base osteomyelitis in patients with head and neck cancer: Diagnosis, management, and outcomes in a case series of 23 patients.
  Czech, M. M., Hwang, P. H., Colevas, A. D., Fischbein, N., & Ho, D. Y. (2022). Skull base osteomyelitis in patients with head and neck cancer: Diagnosis, management, and outcomes in a case series of 23 patients. Laryngoscope Investigative Otolaryngology, 7(1), 47–59.
- NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2022.
  Caudell, J. J., Gillison, M. L., Maghami, E., Spencer, S., Pfister, D. G., Adkins, D., … Darlow, S. D. (2022). NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2022. Journal of the National Comprehensive Cancer Network : JNCCN, 20(3), 224–234.
- Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
  Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Ferris, R. L. (2022). Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. ONCOLOGIST, 27(2), E194–E198.
- A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
  Colevas, A. D., Park, J. J., Fang, B., Shao, J., U'Ren, L., Odegard, J., … Adkins, D. (2022). A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- AI-ASSISTED WHOLE-BODY ASSESSMENT OF IMMUNOTHERAPY RESPONSE USING [18F]F-ARAG, A PET AGENT FOR ACTIVATED T CELLS
  Levi, J., Perk, T., Huynh, L., Packiasamy, J., Cheng, S., Sunwoo, J., & Colevas, A. D. (2021). AI-ASSISTED WHOLE-BODY ASSESSMENT OF IMMUNOTHERAPY RESPONSE USING [18F]F-ARAG, A PET AGENT FOR ACTIVATED T CELLS. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.
- A PHASE 1 TRIAL OF CUE-101, A NOVEL HPV16 E7-PHLA-IL2-FC FUSION PROTEIN, ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/METASTATIC HPV16+HEAD AND NECK CANCER
  Chung, C., Colevas, A. D., Gibson, M., Adkins, D., Sukari, A., Wirth, L., … Pai, S. (2021). A PHASE 1 TRIAL OF CUE-101, A NOVEL HPV16 E7-PHLA-IL2-FC FUSION PROTEIN, ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/METASTATIC HPV16+HEAD AND NECK CANCER. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.
- A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
  McLean, L. S., Morris, T. A., Gramza, A., Liu, S., Khan, S. A., Colevas, A. D., … Rischin, D. (2022). A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. Investigational New Drugs.
- Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
  Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Ferris, R. L. (2022). Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. The Oncologist, 27(2), e194–e198.
- Immunotherapy for Keratinocyte Cancers. Part 1: Immune-Related Epidemiology, Risk Factors, Pathogenesis, and Immunotherapy Management of Keratinocytic Cancers
  Neuner, R., Lee, J., Park, C., Rieger, K. E., Colevas, A. D., & Chang, A. S. (2023). Immunotherapy for Keratinocyte Cancers. Part 1: Immune-Related Epidemiology, Risk Factors, Pathogenesis, and Immunotherapy Management of Keratinocytic Cancers. Journal of the American Academy of Dermatology, 88(6).
- HPV DNA as a biomarker in oropharyngeal cancer: A step in the right direction.
  Colevas, A. D. (2022). HPV DNA as a biomarker in oropharyngeal cancer: A step in the right direction. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Posttreatment FDG-PET/CT Hopkins criteria predict locoregional recurrence after definitive radiotherapy for oropharyngeal squamous cell carcinoma.
  Miller, J. A., Moradi, F., Sundaram, V., Liang, R., Zhang, C., Nguyen, N. K., … Gensheimer, M. F. (2022). Posttreatment FDG-PET/CT Hopkins criteria predict locoregional recurrence after definitive radiotherapy for oropharyngeal squamous cell carcinoma. Head & Neck.
- 89Zr-panitumumab combined with 18F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma.
  Lee, Y.-J., van den Berg, N. S., Duan, H., Azevedo, E. C., Ferri, V., Hom, M., … Rosenthal, E. L. (2022). 89Zr-panitumumab combined with 18F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504.
  Gillison, M. L., Ferris, R. L., Harris, J., Colevas, A. D., Mell, L. K., Kong, C., … Le, Q. T. (2022). Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504. International Journal of Radiation Oncology, Biology, Physics.
- Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment
  Kim, S., Colevas, A. D., Tse, S., On, S., & Cheung, E. (2022). Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A randomized, controlled, open-label, phase 2 study of cemiplimab +/- RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).
  Haydon, A. M., Khushalani, N. I., Robert, C., Brungs, D., Collichio, F. A., Colevas, A. D., … Migden, M. R. (2022). A randomized, controlled, open-label, phase 2 study of cemiplimab +/- RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV+) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).
  Colevas, A. D., Siu, L. L., Lim, D. W.-T., Gao, B., Rojkjaer, L., Katkov, A., … Ma, B. (2022). A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV+) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer.
  Chung, C. H., Colevas, A. D., Adkins, D., Gibson, M. K., Rodriguez, C. P., Sukari, A., … Pai, S. I. (2022). A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.
  Jun, M., Pinto, H., Le, Q.-T. T., Quon, A., Hara, W., Coty, J., … Colevas, A. D. (2023). In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation. PloS One, 18(2), e0276651.
- Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial.
  Lee, N. Y., Harris, J., Kim, J., Garden, A., Mechalakos, J., Pfister, D. G., … Le, Q.-T. (2023). Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial. JAMA Network Open, 6(6), e2316094.
- 7-UP: Generating in silico CODEX from a small set of immunofluorescence markers.
  Wu, E., Trevino, A. E., Wu, Z., Swanson, K., Kim, H. J., D'Angio, H. B., … Zou, J. (2023). 7-UP: Generating in silico CODEX from a small set of immunofluorescence markers. PNAS Nexus, 2(6), pgad171.
- Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cis-platin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.
  Tang, L.-Q., Liu, L.-T., Liu, H., Huang, Y., Jin, F., Xie, S.-Y., … Colevas, A. D. D. (2023). Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cis-platin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer.
  Chung, C. H., Colevas, A. D. D., Adkins, D., Rodriguez, C. P., Park, J. C., Gibson, M. K., … Pai, S. I. (2023). A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus-positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.
  Colevas, A. D. D., Rudek, M. A., Even, C., Lee, V. H.-F., Gillison, M. L., Khan, S. A., … Messick, T. (2023). Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus-positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC
  Colevas, A. D. D., Dinis, J. P., Chin, V. T., Costa, D. A., Park, J. J., Fang, B., … Adkins, D. (2023). A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).
  Sun, L., Cohen, R. B., & Colevas, A. D. D. (2023). Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor.
  Davis, M. T., Anders, N. M., Colevas, A. D., Messick, T. E., & Rudek, M. A. (2023). Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor. Biomedical Chromatography : BMC, e5775.
- A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in EBV plus solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)
  Colevas, A. D., Siu, L., Lim, D. W.-T., Gao, B., Voon, P.-J., Khan, S., … Ma, B. (2023). A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in EBV plus solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). ANNALS OF ONCOLOGY. ELSEVIER.
- A novel mitochondrial-targeted [18F]F-AraG positron emission tomography (PET) biomarker for early diagnosis and monitoring of cardiotoxicity
  Shrestha, U., Chae, H., Blecha, J., Colevas, A. D., Sunwoo, J., VanBrocklin, H., … Seo, Y. (2023). A novel mitochondrial-targeted [18F]F-AraG positron emission tomography (PET) biomarker for early diagnosis and monitoring of cardiotoxicity. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC.
- Nasopharyngeal cancer mortality in disaggregated Asian and non-Asian Americans.
  Hung, G. A., Vohra, S., Kim, G., Jamal, A., Srinivasan, M., Huang, R. J., … Colevas, A. D. (2024). Nasopharyngeal cancer mortality in disaggregated Asian and non-Asian Americans. Head & Neck.
- Nasopharyngeal cancer mortality in disaggregated Asian and non-Asian Americans
  Hung, G. A., Vohra, S., Kim, G., Jamal, A., Srinivasan, M., Huang, R. J., … Colevas, A. D. (2024). Nasopharyngeal cancer mortality in disaggregated Asian and non-Asian Americans. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+head and neck squamous cell cancer (R/M HNSCC).
  Colevas, A. D., Chung, C. H., Adkins, D., Rodriguez, C. P., Park, J. C., Gibson, M. K., … Pai, S. I. (2024). A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+head and neck squamous cell cancer (R/M HNSCC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein-Barr virus-associated nasopharyngeal carcinoma
  Colevas, A. D., Cohen, R. B., Park, J. C., Pfister, D. G., Massarelli, E., Li, Z., … Mehta, A. (2024). Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein-Barr virus-associated nasopharyngeal carcinoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck
  Thomas, J. S., Bruce, J. Y., Li, Z., Lorch, J. H., Phillips, T., Villaflor, V., … Colevas, A. D. (2024). A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
  Sun, L., Cohen, R. B., & Dimitrios Colevas, A. (2024). Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Oral Oncology, 158, 106997.
- Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial.
  Toh, H. C., Yang, M.-H. H., Wang, H.-M. M., Hsieh, C. Y., Chitapanarux, I., Ho, K. F., … Samol, J. (2024). Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- Automated patient selection and care coaches to increase advance care planning for cancer patients.
  Gensheimer, M. F., Teuteberg, W., Patel, M. I., Gupta, D., Noroozi, M., Ling, X., … Ramchandran, K. (2024). Automated patient selection and care coaches to increase advance care planning for cancer patients. Journal of the National Cancer Institute.
- Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification.
  Pan, J.-J. J., Mai, H.-Q. Q., Ng, W. T., Hu, C.-S. S., Li, J.-G. G., Chen, X.-Z. Z., … Lee, A. W. (2024). Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. JAMA Oncology.
- Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC)
  Sun, L., Cohen, R., & Colevas, A. D. (2024). Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- A Phase 1 Dose-escalation and Expansion Study of CUE 101, Given As Monotherapy in 3<SUP>rd</SUP> Line and in Combination with Pembrolizumab in 1<SUP>st</SUP> Line Recurrent/Metastatic (R/M) HPV16+Head and Neck Cancer Patients
  Colevas, A. D., Chung, C. H., Adkins, D., Rodriguez, C. P., Park, J. C., Gibson, M. K., … Pai, S. I. (2024). A Phase 1 Dose-escalation and Expansion Study of CUE 101, Given As Monotherapy in 3^rd Line and in Combination with Pembrolizumab in 1^st Line Recurrent/Metastatic (R/M) HPV16+Head and Neck Cancer Patients. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC)
  Colevas, A. D., Kerrigan, K., Chin, V., Rainey, N., Park, J. J., Fang, B., … Adkins, D. (2024). Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study.
  Flanagan, K. C., Earls, J., Hiken, J., Wellinghoff, R. L., Ponder, M. M., McLeod, H. L., … Duncavage, E. J. (2024). Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study. Journal for Immunotherapy of Cancer, 12(11).
- A Survival Analysis of Patients with Radiation -Induced Cancers after Prior Radiation for Head and Neck Cancer
  Laseinde, E., Guan, L., Hildebrand, R., Meurice, N., Gensheimer, M. F., Beadle, B. M., … Le, Q. T. (2024). A Survival Analysis of Patients with Radiation -Induced Cancers after Prior Radiation for Head and Neck Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab Vs Pembrolizumab in First-line Treatment of Head and Neck Cancer

A Phase 3 Study to Evaluate Petosemtamab Compared with Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

BIBW 2992 (Afatinib) in Head & Neck Cancer

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Imaging and Biomarkers of Hypoxia in Solid Tumors

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Oral Rigosertib for Squamous Cell Carcinoma

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

FNA Tumor Sampling for CD137 Modulation: A Pilot Study

Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Phase 1 Trial of Oral Ixabepilone

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study

Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

A Study in Advanced Cancer

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Specializing In

Practice Locations

Head and Neck Cancer Program at 900 Blake Wilbur Palo Alto, CA

Palo Alto, CA

Head and Neck Cancer Program at 900 Blake Wilbur

900 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(66 Ratings)

Overall Rating

4.9/5

View Ratings by Category

5.0/5

Friendliness

4.9/5

Explanations

4.9/5

Listens

4.8/5

Care provider's efforts to include you in decisions about your care

4.9/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(154 reviews)

Wonderful doctors and staff!

Nov 2024

•

Verified SHC Patient

Great Doctor

Aug 2024

•

Verified SHC Patient

very effective

Jul 2024

•

Verified SHC Patient

Excellent care for 9 years!

May 2024

•

Verified SHC Patient

He's thorough

May 2024

•

Verified SHC Patient

I would recommend Dr Colevas without reservation.

Apr 2024

•

Verified SHC Patient

Iâ€™m quite impressed with his knowledge his manner of speaking so you can understand comes across that the patient really matters

Mar 2024

•

Verified SHC Patient

Excellent MD, sound advice.

Jan 2024

•

Verified SHC Patient

He is an excellent physician and outstanding human being. His humor and storytelling are valuable to provide information and a human touch in difficult conversations.

Jan 2024

•

Verified SHC Patient

He is absolutely wonderful

Dec 2023

•

Verified SHC Patient

Excellent

Dec 2023

•

Verified SHC Patient

He was very warm and informative. Both my wife and I walked out of the visit saying he was great.

Aug 2023

•

Verified SHC Patient

Excellent head and neck oncologist enabling a thoughtful discussion about treatment options moving forward. I totally trust his opinion.

Jul 2023

•

Verified SHC Patient

Switching my care to Stanford from Sutter based on this visit.

May 2023

•

Verified SHC Patient

Dr Colevas very thorough, knowledgeable

Apr 2023

•

Verified SHC Patient

The tesm is doing outstanding.

Jan 2023

•

Verified SHC Patient

Listened very carefully

Dec 2022

•

Verified SHC Patient

Phenomenal team!

Dec 2022

•

Verified SHC Patient

Dr. Colevas is an outstanding Oncologist.

Oct 2022

•

Verified SHC Patient

He answered most of my concerns but had not viewed the film from my recent MRI so was at a disadvantage.

Sep 2022

•

Verified SHC Patient

Dr.Colevas is the best Doctor I ever had. After visiting with him I feel like a brand man weather my visit way bad news. I.always look forward to my appointment. I have been seeing him for over 10 years

Sep 2022

•

Verified SHC Patient

Dr. Colevas and Stanford continue to an amazing team of medical professionals. He is direct but not rude. He gives excellent analogies and takes a complex medical issue and can convey into understandable terms.

Aug 2022

•

Verified SHC Patient

Dr Colevas seems to be very involved with my treatments and well-being. On a personal note Dr C has helped me feel better about my illness and given me someone to talk to about things.

Aug 2022

•

Verified SHC Patient

Exceptional doctor in expertise, resource, and compassion.

Jul 2022

•

Verified SHC Patient

I thought Dr Colevas was a very good doctor.

Jul 2022

•

Verified SHC Patient

He is an outstanding doctor.

Jul 2022

•

Verified SHC Patient

Dr Colevas was excellent. He covered all my issues and seemed comfortable with the technology. I never felt hurried along. In all, I was very pleased with the video visit and appreciated not having to drive to Palo Alto, which is a 3-4 hour round trip.

Jun 2022

•

Verified SHC Patient

Very knowledgeable, caring, easy to talk to

May 2022

•

Verified SHC Patient

Dr. Colevas has always been great. Could never have a problem with him. Very smart person, and makes you feel that all your concerns were answered.

May 2022

•

Verified SHC Patient

Excellent Hospital

Apr 2022

•

Verified SHC Patient

I am always treated well at Stanford

Mar 2022

•

Verified SHC Patient

Dr. Colevas is a extremely competent and considerate individual who truly cares about his patients.

Mar 2022

•

Verified SHC Patient

It was a pleasure to meet Dr. Colevas. He listened, engaged with me, and showed me scans and explained the images. I left the appointment confident that my cancer will be well managed.

Feb 2022

•

Verified SHC Patient

Excellent oncologist - trust his judgement.

Feb 2022

•

Verified SHC Patient

The best doctor and care team!

Feb 2022

•

Verified SHC Patient

The doctor is excellent

Jan 2022

•

Verified SHC Patient

very good!

Dec 2021

•

Verified SHC Patient

Dr Colevas is excellent by any standard. Engaging, knowledgeable, and effective.

Nov 2021

•

Verified SHC Patient

Dr. Colevas is always very helpful to me and I would recommend him to everyone.

Nov 2021

•

Verified SHC Patient

Dr Colevas is a wonderful doctor and I like him very much. But heâ€™s so busy and seldom can be on time for the appointment. Thatâ€™s why I wonâ€™t recommenced him to any one.

Nov 2021

•

Verified SHC Patient

I am always telling people how wonderful it is to go to Stanford

Oct 2021

•

Verified SHC Patient

Dr. Colevas always takes time to explain test results to me until I understand them.

May 2021

•

Verified SHC Patient

Have a wonderful Sabbatical. Iâ€™ll miss seeing you this time. Thank you for everything !

May 2021

•

Verified SHC Patient

Dr, Colevas saved my life from cancer. He is an expert in the field. He treated my condition with care and passion. I am so blessed to be his patient.

May 2021

•

Verified SHC Patient

Good experience.

Apr 2021

•

Verified SHC Patient

Outstanding doctor. Is personable and a pleasure to work with. Communicates and follows up very well. Answers any questions or concerns I may have in easy to understand terms. I have complete faith in Dr. Colevas capabilities and judgement.

Apr 2021

•

Verified SHC Patient

Strongly recommended to others.

Nov 2020

•

Verified SHC Patient

Dr. Colevas is awesome!

Nov 2020

•

Verified SHC Patient

Excellent!

Nov 2020

•

Verified SHC Patient

The doctor & PA were very informative.

Sep 2020

•

Verified SHC Patient

Dr. Colevas, has always cared for my health he answered all my concerns and explained my health condition to where I could understand everything.

Aug 2020

•

Verified SHC Patient

Extremely attentive.

Apr 2020

•

Verified SHC Patient

Everything was very precise and well organized.

Apr 2020

•

Verified SHC Patient

Very good.

Apr 2020

•

Verified SHC Patient

Highly recommend great doctor.

Jan 2020

•

Verified SHC Patient

Very good.

Dec 2019

•

Verified SHC Patient

Best dr.!!

Oct 2019

•

Verified SHC Patient

100% likely.

Oct 2019

•

Verified SHC Patient

Dr. Colevas complete & informative, as ALWAYS.

Oct 2019

•

Verified SHC Patient

Knowledgeable. Exceptional interpersonal skills.

Aug 2019

•

Verified SHC Patient

Dr. Colevas & NP Jessie Coty are a great team who are on OUR team. We rely on them for honesty, directness & guidance which they give us.

Jul 2019

•

Verified SHC Patient

I tell people how pleased I am to be treated by this care provider but I do not feel it my place to make recommendations to others for their care.

Jun 2019

•

Verified SHC Patient

Dr. Colevas demonstrates expertise, candor, compassion, & humor. He took extra time with me on this date to explain complex medical issue sin understandable fashion & to address my every concern. I cannot speak highly enough of Dr. Colevas or of Jesse Coly, his NP.

Jun 2019

•

Verified SHC Patient

I cannot say enough good - great things Dr. Colevas & staff.

May 2019

•

Verified SHC Patient

Dr. Colevas - why I came to Stanford for my condition!

Apr 2019

•

Verified SHC Patient

I credit your team and doctors Colevas and Kaplan with saving my life. What more can I say?

Mar 2019

•

Verified SHC Patient

Dr. Colevas is a great doctor and always cares for his patients.

Mar 2019

•

Verified SHC Patient

Great experience for such a large institution.

Feb 2019

•

Verified SHC Patient

Dr. Colevas seemed rude and condescending NOT to me but to the intern/resident who preceded him in interviewing me. That person was very pleasant and nice to me. Dr. Colevas did seem to go out of his way to talk with my CPMC oncologist, Dr. Kim, about interrupting use of my melanoma medicine in preparation for surgery at Stanford.

Feb 2019

•

Verified SHC Patient

Dr. Colevas always explains test results very good and answers any questions I have about any of them.

Feb 2019

•

Verified SHC Patient

Dr. Colevas was very thorough, can't believe how much time he spent explaining my situation. Much appreciated!!

Jan 2019

•

Verified SHC Patient

Very GOOD.

Dec 2018

•

Verified SHC Patient

The doctor very clearly explained conditions and options. He suspected a complication, referred to hearing specialist, and made medication adjustments, after hours.

Dec 2018

•

Verified SHC Patient

Dr. Colevas is always fabulous: caring, funny, expert, thorough - everything we could want in a doctor.

Nov 2018

•

Verified SHC Patient

Dr. doesn't rush - takes his time.

Nov 2018

•

Verified SHC Patient

I feel I am really good hands.

Nov 2018

•

Verified SHC Patient

Initial experience were very good. As cancer progresses he seems to lose interest.

Nov 2018

•

Verified SHC Patient

Dr. Colevas always gave me choices in my treatment!

Oct 2018

•

Verified SHC Patient

Dr. Colevas is the best!

Oct 2018

•

Verified SHC Patient

Dr. Colevas is the best doctor. He is very thorough.

Oct 2018

•

Verified SHC Patient

Dr. Colevas always has the time and patience to answer my questions. He is also straight up and gives his honest opinion -

Sep 2018

•

Verified SHC Patient

My doctor and his staff are wonderful. Very caring and compassionate.

Sep 2018

•

Verified SHC Patient

I call Dr. Colevas "God". His expertise, compassion, big hearted.... He is complete. Perfect human doctor. Thank you.

Aug 2018

•

Verified SHC Patient

I have full confidence in Dr. Colevas. He is the best doctor.

Aug 2018

•

Verified SHC Patient

Dr. Colevas was wonderful. I always felt fully informed every step of the way. Jessie is super amazing and caring.

Aug 2018

•

Verified SHC Patient

Dr. Colevas is highly professional, yet way down to earth and caring. He is excellent. Stanford is lucky to have him.

Jul 2018

•

Verified SHC Patient

Dr. Colevas, Shelley Stratford & the rest of the team are always so professional, caring and respectful!

Jun 2018

•

Verified SHC Patient

I would highly recommend Dr. Colevas and his team!!!

Jun 2018

•

Verified SHC Patient

GOOD.

Jun 2018

•

Verified SHC Patient

Dr. Colevas and his staff are always professional, empathetic and informative.

Mar 2018

•

Verified SHC Patient

I thought Dr. Colevas & his staff were extraordinarily helpful and provided all the time needed.

Mar 2018

•

Verified SHC Patient

Care provider is great. Exceptional interpersonal skills and knowledge

Mar 2018

•

Verified SHC Patient

Dr. Colevas is excellent.

Mar 2018

•

Verified SHC Patient

Dr. Colevas is great.

Feb 2018

•

Verified SHC Patient

Dr. Colevas is the best!

Feb 2018

•

Verified SHC Patient

Loved that he wasn't in a hurry.

Feb 2018

•

Verified SHC Patient

Dr. Colevas and Jesse Cody are both wonderful.

Feb 2018

•

Verified SHC Patient

Dr. Colevas in the best and very helpful in all explanations.

Nov 2017

•

Verified SHC Patient

Like that never in a hurry takes his time...

Nov 2017

•

Verified SHC Patient

Consultation was explained to me without difficulty in understanding of problem. Feel very confident of care that will be given me.

Nov 2017

•

Verified SHC Patient

Courtesy very good.

Oct 2017

•

Verified SHC Patient

Thorough - provides feedback, follow-up excellent. Feel special.

Oct 2017

•

Verified SHC Patient

Awesome staff.

Aug 2017

•

Verified SHC Patient

Great!

Aug 2017

•

Verified SHC Patient

Dr. Colevas is very thorough.

Aug 2017

•

Verified SHC Patient

Excellent care & personal empathy. Dr. Colevas and Jessie Cody are terrific!

Jul 2017

•

Verified SHC Patient

Very compassionate care!

May 2017

•

Verified SHC Patient

Very impressive team of medical professionals including interns.

May 2017

•

Verified SHC Patient

I appreciate the fact that Dr. Colevas didn't "sugar coat" the highly disturbing and discomforting side effects of my upcoming immunotherapy drug that will be administered to me.

May 2017

•

Verified SHC Patient

Dr. Colevas is the best care provider (fro head and neck) for me. He is gentle and kind. His expertise is excellent! Thank you, Dr. Colevas.

Apr 2017

•

Verified SHC Patient

My team team is very impressive. I value Dr. Colevas & the way he runs his team.

Mar 2017

•

Verified SHC Patient

Excellent service all around

Feb 2017

•

Verified SHC Patient

very thorough examination

Dec 2016

•

Verified SHC Patient

Good.

Dec 2016

•

Verified SHC Patient

Wonderful - did not rush through (see why I waited almost an hour) takes time with patients.

Nov 2016

•

Verified SHC Patient

Overall-excellent!

Nov 2016

•

Verified SHC Patient

Very good dr. He spents time to express yourself to him - Answer questions clearly. Knowledgeable.

Oct 2016

•

Verified SHC Patient

Very smart, and willing to discuss medicine, issues and the overall truth!

Sep 2016

•

Verified SHC Patient

I feel I am in good hands @ Stanford. It helps make me be less anxious.

Sep 2016

•

Verified SHC Patient

We met with a surgeon, oncologist & pain management doctor. Everyone seemed to show genuine concern for my daughter well being.

Aug 2016

•

Verified SHC Patient

Both Dr. Colevas & resident Shyam Patel paid full attention to me - listened to me, answered my questions & were pleasant & funny too.

Aug 2016

•

Verified SHC Patient

Very good.

Aug 2016

•

Verified SHC Patient

My doctor is nice, good & approachable & he explain good about my result of my scan.

Jul 2016

•

Verified SHC Patient

All great.

Jul 2016

•

Verified SHC Patient

I felt like the appointment/exam was rushed by Dr. Colevas, did not feel like he remembered me/my case, talked more to his Nurse Practitioner than to me, and little interest in whether I had any questions or concerns. On the other hand, I LOVE Dr. Orloff, Dr. Kizner and Dr. Hancock! and their teams.

May 2016

•

Verified SHC Patient

I know this look good, but it doesn't convey how caring Dr. Colevas is. They are the best.

Apr 2016

•

Verified SHC Patient

Only good experience.

Apr 2016

•

Verified SHC Patient

Everybody who treat me is great.

Mar 2016

•

Verified SHC Patient

Doctors are very friendly & approachable.

Mar 2016

•

Verified SHC Patient

I have supreme confidence in the care, competence and compassion that my team gives me: Drs Holsinger, Colevas,Akatsu and Heather Starmer "the mircale worker"

Mar 2016

•

Verified SHC Patient

very professional staff

Feb 2016

•

Verified SHC Patient

Always takes lots of time with me as his patient.

Feb 2016

•

Verified SHC Patient

Dr. Colevas is an outstanding doctor. He always takes, the time to make sure we have all the information we need to make decisions. I would highly recommend him!

Feb 2016

•

Verified SHC Patient

Amazing/awesome love this office!

Feb 2016

•

Verified SHC Patient

Good.

Feb 2016

•

Verified SHC Patient

Dr Colevas explains things very good and always speaks to me with genuine concern and doesn't hold back, he tells it like it as and I respect that. He is one of my favorites.

Jan 2016

•

Verified SHC Patient

Dr. Colevas is awesome. He explains everything in the right amount of detail!

Jan 2016

•

Verified SHC Patient

Everyone friendly. Very happy all good thank you.

Jan 2016

•

Verified SHC Patient

I have to travel 4 1/2 hours one way for this office visits yet I still do it cause I TRUST YOU WITH MY LIFE.

Sep 2015

•

Verified SHC Patient

I have been experiencing Dr. Colevas's compassion and care for my health which means a lot to me!! Thanks.

Aug 2015

•

Verified SHC Patient

All is good -

Jun 2015

•

Verified SHC Patient

Overall experience was excellent. I was treated with compassion & sympathy. Everybody was friendly & accommodating. Thanks to all of them -

Jun 2015

•

Verified SHC Patient

Dr. Colevas was a very friendly & knowledgeable provider, & I feel very confident in him as a doctor.

Apr 2015

•

Verified SHC Patient

I feel like I owe my life to my care providers - and to Dr. Colevas in particular.

Apr 2015

•

Verified SHC Patient

Very good.

Mar 2015

•

Verified SHC Patient

I give Dr Colevas 5 Stars he is a great Dr.

Mar 2015

•

Verified SHC Patient

Dr. Colevas is very down to Earth & informative. Very caring & compassionate.

Mar 2015

•

Verified SHC Patient

Very good; side-effects of Rx not made clear - those effects caused me to discontinue taking.

Feb 2015

•

Verified SHC Patient

Dr. Colevas & staff are all extraordinary.

Jan 2015

•

Verified SHC Patient

Does not rush takes as much time as you need to answer questions.

Nov 2014

•

Verified SHC Patient

I have complete faith in Dr. Colevas and all that I've worked with.

Nov 2014

•

Verified SHC Patient

There was no follow-up care needed.

Aug 2014

•

Verified SHC Patient

Dr. Colevas great & Dr. Chris Holsinger great.

Mar 2014

•

Verified SHC Patient

Very well informed.

Feb 2014

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

A. Dimitrios Colevas, MD

Medical oncologist, Head and neck specialist, Cutaneous oncology specialist

Get In Touch

Professional Summary

Education & Certifications

Publications

Clinical Trials

Specializing In

Practice Locations

Head and Neck Cancer Program at 900 Blake Wilbur Palo Alto, CA

Head and Neck Cancer Program at 900 Blake Wilbur

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(154 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

A. Dimitrios Colevas, MD

Medical oncologist, Head and neck specialist, Cutaneous oncology specialist

Get In Touch

Professional Summary

Education & Certifications

Publications

Clinical Trials

Specializing In

Practice Locations

Head and Neck Cancer Program at 900 Blake Wilbur Palo Alto, CA

Head and Neck Cancer Program at 900 Blake Wilbur

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(154 reviews)

Referring Physicians

PHYSICIAN HELPLINE